CO7160082A2 - Un método para mejorar la función hepática - Google Patents

Un método para mejorar la función hepática

Info

Publication number
CO7160082A2
CO7160082A2 CO14279764A CO14279764A CO7160082A2 CO 7160082 A2 CO7160082 A2 CO 7160082A2 CO 14279764 A CO14279764 A CO 14279764A CO 14279764 A CO14279764 A CO 14279764A CO 7160082 A2 CO7160082 A2 CO 7160082A2
Authority
CO
Colombia
Prior art keywords
dementia
salt
disease
liver function
improve liver
Prior art date
Application number
CO14279764A
Other languages
English (en)
Inventor
Ken Walder
Guy Krippner
Geoff Nicholson
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of CO7160082A2 publication Critical patent/CO7160082A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una sal de tipo camsilato de (1r,1’R,4R)-4-metoxi-5’’-metil-6’-[5-(prop-1-in-1-il)piridin-3-il]-3’Hdiespiro[ciclohexano-1,2’-inden-1’2’-imidazol]-4’’-amina,composiciones farmacéuticas que contienen la sal y usosterapéuticos de la sal para tratar patologías relacionadas conAβ tales como la enfermedad de Alzheimer, síndrome de Down,angiopatía β-amiloide y afecciones tales como la demenciaincluida la demencia de origen mixto vascular y degenerativo,demencia presenil, demencia senil y demencia asociada con laenfermedad de Parkinson, parálisis supranuclear progresiva odegeneración corticobasal.
CO14279764A 2012-05-24 2014-12-19 Un método para mejorar la función hepática CO7160082A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US201261666574P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
CO7160082A2 true CO7160082A2 (es) 2015-01-15

Family

ID=49622927

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14279764A CO7160082A2 (es) 2012-05-24 2014-12-19 Un método para mejorar la función hepática

Country Status (15)

Country Link
US (2) US20150150855A1 (es)
EP (1) EP2854807A4 (es)
JP (2) JP6360826B2 (es)
KR (1) KR20150023405A (es)
CN (2) CN109498623A (es)
BR (1) BR112014029308A2 (es)
CA (1) CA2874513A1 (es)
CO (1) CO7160082A2 (es)
HK (1) HK1209051A1 (es)
MX (1) MX362111B (es)
NZ (2) NZ723206A (es)
RU (1) RU2653478C2 (es)
SG (2) SG10201705388XA (es)
WO (1) WO2013173859A1 (es)
ZA (1) ZA201408704B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
EP2854806A4 (en) * 2012-05-24 2015-11-18 Verva Pharmaceuticals Ltd METHOD OF WEIGHT REDUCTION
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
PL2106260T3 (pl) * 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
EP2854806A4 (en) * 2012-05-24 2015-11-18 Verva Pharmaceuticals Ltd METHOD OF WEIGHT REDUCTION

Also Published As

Publication number Publication date
KR20150023405A (ko) 2015-03-05
SG10201705388XA (en) 2017-07-28
JP6360826B2 (ja) 2018-07-18
RU2014152196A (ru) 2016-07-20
MX2014014317A (es) 2015-08-10
CN104487073A (zh) 2015-04-01
NZ723206A (en) 2018-02-23
CA2874513A1 (en) 2013-11-28
WO2013173859A1 (en) 2013-11-28
JP6412241B2 (ja) 2018-10-24
JP2018090589A (ja) 2018-06-14
CN109498623A (zh) 2019-03-22
ZA201408704B (en) 2018-07-25
BR112014029308A2 (pt) 2017-06-27
US20150150855A1 (en) 2015-06-04
RU2653478C2 (ru) 2018-05-08
JP2015517534A (ja) 2015-06-22
EP2854807A4 (en) 2016-03-16
NZ702645A (en) 2016-08-26
US20180333399A1 (en) 2018-11-22
EP2854807A1 (en) 2015-04-08
MX362111B (es) 2019-01-07
HK1209051A1 (en) 2016-03-24
SG11201407787VA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
ECSP14032215A (es) Sal de tipo camsilato
MX2017002626A (es) Composicion que contiene una mezcla de extractos vegetales o una mezcla de moleculas contenidas en dichas plantas y uso para controlar el metabolismo de glucidos y/o lipidos.
UA110354C2 (uk) Противірусні сполуки
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
IN2015DN00137A (es)
CO2017004465A2 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2013010170A (es) Moduladores heterociclicos de sintesis lipidica.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
WO2012097116A3 (en) Isotopologues of isoindole derivatives
CO7160082A2 (es) Un método para mejorar la función hepática
IN2014DN09584A (es)
CO7160083A2 (es) Método de reducción de peso
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
MX2016005645A (es) Composicion farmaceutica topica de acitretina.
IL234616A0 (en) A herbal preparation for the treatment of metabolic diseases
IN2014KN00865A (es)
WO2013129977A3 (ru) Фармацевтический состав для инъекций, обладающий нейропротекторной, антиамнестической, антиоксидантной, противогипоксической, противоишемической активностью (варианты)
CU20130083A7 (es) Compuestos y su uso como inhibidores de bace
WO2013114403A8 (en) Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders
CL2008000668A1 (es) Compuestos derivados de 3-ciano-4-(4-fenil-piperidin-1-il)piridin-2-ona; proceso de preparacion; composicion farmaceutica que los comprende; y su uso para tratar trastornos del sistema nervioso central.
AU348425S (en) A loft bed